People must have fully recovered from the acute poisonous effects of all prior anti-most cancers therapy and have to satisfy the next minimal period from prior anti-cancer directed therapy just before enrollment. Experimental: Dose expansion_sub-inhabitants 2_lower dose of niraparib MTDs and/or prospect RP2Ds for elimusertib utilised together with niraparib in https://apalutamide99865.ambien-blog.com/32836733/new-step-by-step-map-for-elimusertib